Compile Data Set for Download or QSAR
Report error Found 569 Enz. Inhib. hit(s) with all data for entry = 11362
TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511691(US11084800, Cpd No. 1 | US11708351, Compound 1)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511698(US11084800, Cpd No. 3 | (1s,4s)-2-(2-(3-acetyl-5-(...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511699(US11084800, Cpd No. 4 | (3S)-2-(2-(3-acetyl-5-(2- ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511700(US11084800, Cpd No. 5 | (3S)-5-(6-azaspiro[2.5]oct...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511701(US11084800, Cpd No. 6 | (3S)-2-(2-(3-acetyl-5-(2- ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511703(US11084800, Cpd No. 8 | US11708351, Compound 8)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511704(US11084800, Cpd No. 9 | (1R,3S,5R)-2-(2-(3-acetyl-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511706(US11084800, Cpd No. 11 | (3S)-2-(2-(3-acetyl-5-(2-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511707(US11084800, Cpd No. 12 | (3S)-5-(3-azabicyclo[3.1....)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511708(US11084800, Cpd No. 13 | (3S)-5-(2-azaspiro[3.3]he...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511709(US11084800, Cpd No. 14 | (1R,3S,5R)-2-(2-(3-acetyl...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511710(US11084800, Cpd No. 15 | (1R,3S,5R)-2-(2-(3-acetyl...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM609810(US11708351, Compound 17 | (1R,3S,5R)-2-(2- (3-acet...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511713(US11084800, Cpd No. 18 | (1R,3S,5R)-2-(2-(3-acetyl...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511714(US11084800, Cpd No. 19 | (2S,4R)-1-(2-(3-acetyl-7-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511715(US11084800, Cpd No. 20 | (2S,4R)-1-(2-(3-acetyl-7-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511716(US11084800, Cpd No. 21 | (2S,4R)-1-(2-(3-acetyl-7-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511717(US11084800, Cpd No. 22 | (3S)-2-(2-(3-acetyl-5-(2-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511718(US11084800, Cpd No. 23 | (2S,4R)-1-(2-(3-acetyl-5-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511719(US11084800, Cpd No. 24 | (3S)-2-(2-(3-acetyl-5-(2-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511720(US11084800, Cpd No. 25 | methyl 3-acetyl-1-(2-((2S...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511722(US11084800, Cpd No. 27 | (1R,3S,5R)-2-(2-(3-acetyl...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM609823(US11708351, Compound 28 | (1R,3S,5R)-2-(2- (3-acet...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511724(US11084800, Cpd No. 29 | (1S,3S,5R)-2-(2-(3-acetyl...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511725(US11084800, Cpd No. 31 | (1R,3S,5R)-2-(2-(3-acetyl...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511726(US11084800, Cpd No. 32 | (3S)-2-(2-(3-acetyl-7-(me...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511727(US11084800, Cpd No. 33 | (1R,3S,5R)-2-(2-(3-acetyl...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511728(US11084800, Cpd No. 34 | (1R,3S,5R)-2-(2-(3-acetyl...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511729(US11084800, Cpd No. 35 | (1R,3S,5R)-2-(2-(3-acetyl...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511730(US11084800, Cpd No. 36 | (1R,3S,5R)-2-(2-(3-acetyl...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511731(US11084800, Cpd No. 37 | (1R,3S,5R)-2-(2-(3-acetyl...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511732(US11084800, Cpd No. 38 | (1R,3S,5R)-2-(2-(3-acetyl...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511733(US11084800, Cpd No. 39 | (1R,3S,5R)-2-(2-(3-acetyl...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM609838(US11708351, Compound 41 | 3-acetyl-1-(2- ((2S,4R)-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511736(US11084800, Cpd No. 42 | (3S)-2-(2-(3-acetyl-5-(2-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511738(US11084800, Cpd No. 44 | (1R,3S,5R)-5-(acetamidome...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511739(BDBM609843 | methyl ((2S)-1-((((3S)-2-(2-(3-acetyl...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511740(US11084800, Cpd No. 46 | (1R,3S,5R)-2-(2-(3-acetyl...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511741(US11084800, Cpd No. 47 | (1R,3S,5R)-2-(2-(3-acetyl...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511743(US11084800, Cpd No. 49 | (3S)-2-(2-(3-acetyl-5-(2-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511744(US11084800, Cpd No. 50 | 5-(3-acetyl-1-(2-((1R,3S,...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511745(US11084800, Cpd No. 52 | (1R,3S,5R)-2-(2-(3-acetyl...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511746(US11084800, Cpd No. 54 | (1R,3S,5R)-2-(2-(3-acetyl...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511747(US11084800, Cpd No. 55 | 1-(2-((1R,3S,5R)-3-((6-br...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511748(US11084800, Cpd No. 56 | 1-(2-((1R,2S,5S)-2-((6-br...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511749(US11084800, Cpd No. 57 | 1-(2-((1R,3S,5R)-3-((6-br...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511750(US11084800, Cpd No. 58 | 1-(2-((1R,3S,5R)-3-((6-br...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511751(US11084800, Cpd No. 61 | methyl 2-(2-((2S,4R)-1-(2...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM511752(US11084800, Cpd No. 62 | 2-(2-((2S,4R)-1-(2-(3-ace...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM609859(US11708351, Compound 64 | 5-(3-acetyl-1-(2- ((1R,3...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
Go to US Patent

Displayed 1 to 50 (of 569 total ) | Next | Last >>
Jump to: